New approaches in angiogenic targeting for colorectal cancer

Table 1 Anti-VEGF agents currently in clinical development

Agent	Targets	Phase of development
Specific anti-VEGF antibodies
Bevacizumab (Avastin)	VEGF-A	Phase III
IMC-C1121b	VEGFR-2	PhaseI-II
VEGF Trap	VEGF, PlGF, VEGF-B	Phase I
Agents that target VEGF receptors tyrosine kinase
Vatalanib (PTK787/ZK 222584)	VEGFR1, VEGFR2, VEGFR3, PDGFR-β, c-Kit	Phase III
Sorafenib (BAY 43-9006)	VEGFR-2, PDGFR-β, FLT3, c-Kit, Raf	Phase III
Sunitinib (SU11248)	VEGFR2, PDGFR-β, FLT3, c-Kit	Phase III
Semaxanib (SU5416)	VEGFR1, VEGFR2	Stopped
AZD2171	VEGFR1, VEGFR2, VEGFR3, PDGFR-β, c-Kit	PhaseI-II
CEP-7055	VEGFR1, VEGFR2, VEGFR3	PhaseI-II
CHIR258	VEGFR1, VEGFR2, FGFR1, FGFR3
CP-547632	VEGFR2	PhaseI-II
GW786034	VEGFR2	PhaseI-II
OSI-930	VEGFR, c-Kit	PhaseI-II
ZK-CDK	VEGFRs, PDGFR, CDKs	PhaseI-II
AG013736	VEGFR, PDGFR-β, c-Kit	PhaseI-II
AMG706	VEGFR1, VEGFR2, PDGFR-β, c-Kit	PhaseI-II
KRN-951	VEGFR1, VEGFR2, VEGFR3, PDGFR-β, c-Kit	PhaseI-II
BMS-582664	VEGFR2, FGFR	PhaseI-II
XL999	FGFR, VEGFRs, PDGFR, FLT3	PhaseI-II
Zactima (ZD6474)	VEGFR2, EGFR, RET	PhaseI-II
AEE788	VEGFR1, VEGFR2, EGFR	PhaseI-II
Antisense oligonucleotides
Veglin (VEGF-AS)	VEGF, VEGF-C, VEGF-D	PhaseI
Aptamer
Aplidin (Dehydrodidemnin B)	VEGF	PhaseI

CDK: Cyclin-dependent kinase; EGFR: Epidermal growth factor receptor; FGFR: Fibroblast growth factor receptor; FLT3: Fms-related tyrosine kinase 3; MMP: Matrix metalloproteinase; PDGFR: Platelet-derived growth factor receptor; PIGF: Placental growth factor; VEGF: Vascular endothelial growth factor.